Ascendis Pharma A (ASND) Income from Continuing Operations (2014 - 2026)
Ascendis Pharma A (ASND) reported Income from Continuing Operations of 736795896.67 for Q1 2026, up 857.21% on a YoY basis from 76972951.65 in Q1 2025, and up 3289.05% sequentially from 23103935.68 in Q4 2025.
Ascendis Pharma A (ASND) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Ascendis Pharma A (ASND) has 13 years of Income from Continuing Operations data on file, last reported at 736795896.67 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 857.21% year-over-year to 736795896.67; the trailing twelve-month figure through Mar 2026 stood at 615578672.64 (up 270.95% YoY), and the FY2025 full-year result was 293738232.63, up 28.22% from the prior year.
- Income from Continuing Operations rose to 736795896.67 in Q1 2026, from 23103935.68 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 736795896.67 in Q1 2026 to a low of 200706122.44 in Q4 2022.
- A 5-year average of 57978002.8 and a median of 106700810.43 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 85.25% in 2022 and soared 857.21% in 2026, its largest moves.
- Tracing ASND's Income from Continuing Operations over 5 years: stood at 200706122.44 in 2022, then soared by 59.64% to 81013971.39 in 2023, then surged by 52.12% to 38788944.43 in 2024, then surged by 40.44% to 23103935.68 in 2025, then surged by 3289.05% to 736795896.67 in 2026.
- Business Quant data shows ASND's Income from Continuing Operations at 736795896.67 in Q1 2026, 23103935.68 in Q4 2025, and 62842556.44 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Ascendis Pharma A | 15.31 Bn | 14.64 Bn | 268.20 Mn | 736.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 736.80 Mn |
| Dec 31, 2025 | -23.10 Mn |
| Sep 30, 2025 | -62.84 Mn |
| Jun 30, 2025 | -35.27 Mn |
| Mar 31, 2025 | -97.30 Mn |
| Dec 31, 2024 | -38.79 Mn |
| Sep 30, 2024 | -106.70 Mn |
| Jun 30, 2024 | -117.30 Mn |
| Mar 31, 2024 | -136.90 Mn |
| Dec 31, 2023 | -81.01 Mn |
| Sep 30, 2023 | -175.19 Mn |
| Jun 30, 2023 | -133.17 Mn |
| Mar 31, 2023 | -116.26 Mn |
| Dec 31, 2022 | -200.71 Mn |
| Sep 30, 2022 | -170.69 Mn |
| Jun 30, 2022 | -86.87 Mn |
| Mar 31, 2022 | -140.31 Mn |
| Dec 31, 2021 | -121.33 Mn |
| Sep 30, 2021 | -94.75 Mn |
| Jun 30, 2021 | -161.82 Mn |